{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:40:52Z","timestamp":1784634052574,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10637-022-01279-7","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T09:02:51Z","timestamp":1657011771000},"page":"1095-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anlotinib plus etoposide and cisplatin\/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study"],"prefix":"10.1007","volume":"40","author":[{"given":"Tiandong","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"1279_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092645","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Di Maio M, Tiseo M (2020) Adding PD-1\/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive Stage Small Cell Lung Cancer (SCLC): A meta-analysis of randomized trials. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12092645","journal-title":"Cancers (Basel)"},{"key":"1279_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112646","author":"A Morabito","year":"2021","unstructured":"Morabito A, Rolfo C (2021) Small cell lung cancer: A new era is beginning? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13112646","journal-title":"Cancers (Basel)"},{"key":"1279_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7:3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"key":"1279_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"1279_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12094-020-02295-w","volume":"22","author":"M Domine","year":"2020","unstructured":"Domine M, Moran T, Isla D, Marti JL, Sullivan I, Provencio M, Olmedo ME, Ponce S, Blasco A, Cobo M (2020) SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol 22:245\u2013255. https:\/\/doi.org\/10.1007\/s12094-020-02295-w","journal-title":"Clin Transl Oncol"},{"key":"1279_CR6","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.3747\/co.26.4481","volume":"26","author":"A Sun","year":"2019","unstructured":"Sun A, Durocher-Allen LD, Ellis PM, Ung YC, Goffin JR, Ramchandar K, Darling G (2019) Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Curr Oncol 26:e372\u2013e384. https:\/\/doi.org\/10.3747\/co.26.4481","journal-title":"Curr Oncol"},{"key":"1279_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D\u2019Amico TA, DeCamp MM, Dilling TJ, Dobelbower M et al (2017) Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:504\u2013535. https:\/\/doi.org\/10.6004\/jnccn.2017.0050","journal-title":"J Natl Compr Canc Netw"},{"key":"1279_CR8","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","volume":"33","author":"CM Rudin","year":"2015","unstructured":"Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT 3rd, Giaccone G (2015) Treatment of small-cell lung cancer: American society of clinical oncology endorsement of the American college of chest physicians guideline. J Clin Oncol 33:4106\u20134111. https:\/\/doi.org\/10.1200\/JCO.2015.63.7918","journal-title":"J Clin Oncol"},{"key":"1279_CR9","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","volume":"21","author":"MC Pietanza","year":"2015","unstructured":"Pietanza MC, Byers LA, Minna JD, Rudin CM (2015) Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21:2244\u20132255. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2958","journal-title":"Clin Cancer Res"},{"key":"1279_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15748","volume":"3","author":"T Zhou","year":"2020","unstructured":"Zhou T, Zhang Z, Luo F, Zhao Y, Hou X, Liu T, Wang K, Zhao H, Huang Y, Zhang L (2020) Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis. JAMA Netw Open 3:e2015748. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15748","journal-title":"JAMA Netw Open"},{"key":"1279_CR11","doi-asserted-by":"publisher","unstructured":"Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, Group EGW (2013) Small-cell lung cancer (SCLC): ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi99\u2013vi105.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdt178","DOI":"10.1093\/annonc\/mdt178"},{"key":"1279_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro CJ, Califano R, Nishio M et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39:619\u2013630. https:\/\/doi.org\/10.1200\/JCO.20.01055","journal-title":"J Clin Oncol"},{"key":"1279_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11:120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7","journal-title":"J Hematol Oncol"},{"key":"1279_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY (2018) Anlotinib: First global approval. Drugs 78:1057\u20131062. https:\/\/doi.org\/10.1007\/s40265-018-0939-x","journal-title":"Drugs"},{"key":"1279_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1089\/thy.2018.0022","volume":"28","author":"Y Sun","year":"2018","unstructured":"Sun Y, Du F, Gao M, Ji Q, Li Z, Zhang Y, Guo Z, Wang J, Chen X, Wang J et al (2018) Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer. Thyroid 28:1455\u20131461. https:\/\/doi.org\/10.1089\/thy.2018.0022","journal-title":"Thyroid"},{"key":"1279_CR16","doi-asserted-by":"crossref","unstructured":"Zhou A-P, Bai Y, Song Y, Li H, Xie X, Ren X-B, Ye D, Liu J, Luo H, Bai X (2016) Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2016.34.15_suppl.e16082"},{"key":"1279_CR17","doi-asserted-by":"crossref","unstructured":"Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng JF, Zhang S, Ba Y, Liu Y (2019) Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2019.37.4_suppl.95"},{"key":"1279_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109:1207\u20131219. https:\/\/doi.org\/10.1111\/cas.13536","journal-title":"Cancer Sci"},{"key":"1279_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","volume":"38","author":"L Liang","year":"2019","unstructured":"Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, Wang L, Xia Y, Qiao Y, Sun W et al (2019) Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 38:71. https:\/\/doi.org\/10.1186\/s13046-019-1093-3","journal-title":"J Exp Clin Cancer Res"},{"key":"1279_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/ERC-17-0558","volume":"26","author":"X Ruan","year":"2019","unstructured":"Ruan X, Shi X, Dong Q, Yu Y, Hou X, Song X, Wei X, Chen L, Gao M (2019) Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer 26:153\u2013164. https:\/\/doi.org\/10.1530\/ERC-17-0558","journal-title":"Endocr Relat Cancer"},{"key":"1279_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.21037\/tlcr-20-1235","volume":"10","author":"Z He","year":"2021","unstructured":"He Z, Zhou H, Wang J, Li D, Zhang X, Wang P, Ma T, Zhang Y, Tian C, Chen Y et al (2021) Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial. Transl Lung Cancer Res 10:889\u2013899. https:\/\/doi.org\/10.21037\/tlcr-20-1235","journal-title":"Transl Lung Cancer Res"},{"key":"1279_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz264.002","volume":"30","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J (2019) Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol 30:v711","journal-title":"Ann Oncol"},{"key":"1279_CR23","doi-asserted-by":"publisher","first-page":"117955492110671","DOI":"10.1177\/11795549211067184","volume":"16","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Z, Sun W, Wang H, Zu J (2022) Effectiveness and Safety of anlotinib monotherapy for patients with extensive-stage small-cell lung cancer who progressed to chemotherapy: A real-world exploratory study. Clin Med Insights Oncol 16:11795549211067184. https:\/\/doi.org\/10.1177\/11795549211067184","journal-title":"Clin Med Insights Oncol"},{"key":"1279_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1279_CR25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","volume":"27","author":"PN Lara Jr","year":"2009","unstructured":"Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR et al (2009) Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530\u20132535. https:\/\/doi.org\/10.1200\/JCO.2008.20.1061","journal-title":"J Clin Oncol"},{"key":"1279_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.mayocp.2019.01.034","volume":"94","author":"S Wang","year":"2019","unstructured":"Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA (2019) Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc 94:1599\u20131622. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.034","journal-title":"Mayo Clin Proc"},{"key":"1279_CR27","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"1279_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655316","author":"A Montanino","year":"2021","unstructured":"Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, Costanzo R, Sandomenico C, Botti G, Piccirillo MC et al (2021) Angiogenesis inhibitors in small cell lung cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.655316","journal-title":"Front Oncol"},{"key":"1279_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4736","author":"P Deng","year":"2022","unstructured":"Deng P, Hu C, Chen C, Cao L, Gu Q, An J, Qin L, Li M, He B, Jiang J et al (2022) Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial. Cancer Med n\/a. https:\/\/doi.org\/10.1002\/cam4.4736","journal-title":"Cancer Med n\/a"},{"key":"1279_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1759-7714.14414","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Liao J, Wu X, Zhao X, Sun S, Wang H, Hu Z, Zhang Y, Yu H, Wang J (2022) A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer. Thorac Cancer 13:1463\u20131470. https:\/\/doi.org\/10.1111\/1759-7714.14414","journal-title":"Thorac Cancer"},{"key":"1279_CR31","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1200\/JCO.2021.39.15_suppl.8569","volume":"39","author":"D Almquist","year":"2021","unstructured":"Almquist D, Langlais B, Yu NY, Sio TTW, Savvides P, Yang P, Schild SE, Mansfield AS, Ernani V (2021) Chemoimmunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with an Eastern Cooperative Group (ECOG) performance status (PS) of two or greater. J Clin Oncol 39:8569\u20138569. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8569","journal-title":"J Clin Oncol"},{"key":"1279_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jgo.2013.07.010","volume":"5","author":"JM Broderick","year":"2014","unstructured":"Broderick JM, Hussey J, Kennedy MJ, O\u2019 Donnell DM (2014) Patients over 65years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different. J Geriatr Oncol 5:49\u201356. https:\/\/doi.org\/10.1016\/j.jgo.2013.07.010","journal-title":"J Geriatr Oncol"},{"key":"1279_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R et al (2017) Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol 35:1281\u20131287. https:\/\/doi.org\/10.1200\/JCO.2016.69.4844","journal-title":"J Clin Oncol"},{"key":"1279_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10637-013-0061-6","volume":"32","author":"N Sharma","year":"2014","unstructured":"Sharma N, Pennell N, Nickolich M, Halmos B, Ma P, Mekhail T, Fu P, Dowlati A (2014) Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs 32:362\u2013368. https:\/\/doi.org\/10.1007\/s10637-013-0061-6","journal-title":"Invest New Drugs"},{"key":"1279_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/JTO.0000000000000343","volume":"10","author":"S Lu","year":"2015","unstructured":"Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X et al (2015) A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol 10:206\u2013211. https:\/\/doi.org\/10.1097\/JTO.0000000000000343","journal-title":"J Thorac Oncol"},{"key":"1279_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10637-019-00828-x","volume":"38","author":"H Luo","year":"2020","unstructured":"Luo H, Zhang L, Yang B, Feng Y, Xiong Y, Zhang S, Li X, Qian C, Dong W, Dai N (2020) A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first\u00adline induction chemotherapy in extensive\u00ad stage small cell lung cancer. Invest New Drugs 38:148\u2013159. https:\/\/doi.org\/10.1007\/s10637-019-00828-x","journal-title":"Invest New Drugs"},{"key":"1279_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Lu N (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene 654:77\u201386. https:\/\/doi.org\/10.1016\/j.gene.2018.02.026","journal-title":"Gene"},{"key":"1279_CR38","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/jco.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA (2011) Randomized phase ii study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE Trial. J Clin Oncol 29:2215\u20132222. https:\/\/doi.org\/10.1200\/jco.2010.29.3423","journal-title":"J Clin Oncol"},{"key":"1279_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jtho.2019.01.010","volume":"14","author":"M Reck","year":"2019","unstructured":"Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhasz E, Kowalski D, Robinet G, Cadranel J, Bidoli P et al (2019) Phase II study of roniciclib in combination with cisplatin\/etoposide or carboplatin\/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J Thorac Oncol 14:701\u2013711. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.010","journal-title":"J Thorac Oncol"},{"key":"1279_CR40","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1186\/s12885-021-09034-6","volume":"21","author":"S Jiang","year":"2021","unstructured":"Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z (2021) Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer 21:1308. https:\/\/doi.org\/10.1186\/s12885-021-09034-6","journal-title":"BMC Cancer"},{"key":"1279_CR41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","volume":"20","author":"Y Gao","year":"2020","unstructured":"Gao Y, Liu P, Shi R (2020) Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 20:1001\u20131014. https:\/\/doi.org\/10.3892\/ol.2020.11685","journal-title":"Oncol Lett"},{"key":"1279_CR42","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"AP Zhou","year":"2019","unstructured":"Zhou AP, Bai Y, Song Y, Luo H, Ren XB, Wang X, Shi B, Fu C, Cheng Y, Liu J et al (2019) Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase ii clinical trial. Oncologist 24:e702\u2013e708. https:\/\/doi.org\/10.1634\/theoncologist.2018-0839","journal-title":"Oncologist"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01279-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:49:31Z","timestamp":1678510171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01279-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01279-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the \"Declaration of Helsinki\". Ethics approval is obtained from the medical ethics committee of the Third People's Hospital of Zhengzhou city.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}